ACIP voted to recommend against anyone — adult, child and pregnant person — receiving a seasonal flu vaccine with the mercury ...

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

Cracking the genome's switchboard: How AI helps decode gene regulation. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more. Your name. Note.

Garcia: So last week, the FDA approved a monoclonal antibody called clesrovimab, which helps prevent RSV in newborns and infants during their first RSV season. Now, this is the second monoclonal ...

Figure 1.In planta RNP-mediated genome editing in melon.(A) Microprojectile-mediated transfer of a GFP expression plasmid into melon SAMs.(B) Schematic outline of the iPB-RNP method for genome editing ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education. As the field of RSV prevention continues to grow, pediatricians face both new ...

Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna. June 12, 2025.

The researchers noted demographic and illness characteristics were similar between patients with RSV type A and those with RSV type B. The estimated overall seasonal incidence of outpatient ...

The ribosome is essential for protein synthesis and targeting its function serves as a platform for many therapies. Resistance gene-guided genome mining for a priori target identification has emerged ...

RSV contains a nonsegmented negative-sense RNA genome, which requires the virus-encoded RNA-dependent RNA polymerase (RdRp) complex for genome replication and transcription of viral RNA. (17) Three ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection. The Food and Drug Administration (FDA) expanded the ...